LAZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Lazard Inc (LAZ) is not a strong buy for a beginner, long-term investor at this time. While the stock has some positive aspects, such as a diversified business model and strong market position, the recent financial performance and technical indicators do not support a compelling entry point. Additionally, the lack of significant trading signals and potential downside risks in the short term suggest holding off on investing right now.
The MACD is negative and contracting, RSI is neutral at 58.152, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot point of 52.008, with resistance at 54.868 and support at 49.149. Short-term stock trend analysis suggests a potential decline of -1.83% in the next day and -5.15% in the next week.
Analysts have raised price targets recently, with some maintaining Outperform and Buy ratings.
Lazard's diversified business model and strong market position with $267 billion in client assets.
Global M&A activity has surged, which could benefit Lazard's advisory business.
Recent financial performance shows significant declines in revenue (-4.10% YoY), net income (-40.75% YoY), and EPS (-42.50% YoY).
The stock has a 70% chance of declining in the short term, based on candlestick pattern analysis.
The MACD and RSI indicators do not show a strong bullish signal.
The fund's distribution includes a high return of capital (64.7%), which may pressure future returns.
In Q4 2025, Lazard's revenue dropped to $808.68 million (-4.10% YoY), net income fell to $49.86 million (-40.75% YoY), and EPS declined to $0.46 (-42.50% YoY). Gross margin remained relatively stable at 97.2% (-0.17% YoY). These results indicate weak financial performance in the latest quarter.
Recent analyst activity shows mixed sentiment. UBS raised its price target to $59 with a Neutral rating, while Keefe Bruyette raised its target to $62 with an Outperform rating. BofA initiated coverage with a Buy rating and a $65 price target, citing Lazard's diversified business model and potential turnaround. However, Morgan Stanley lowered its price target to $59 and maintains an Underweight rating, citing weaker Q4 estimates.
